KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) FCF Margin (2016 - 2025)

Acadia Pharmaceuticals has reported FCF Margin over the past 16 years, most recently at 18.57% for Q4 2025.

  • Quarterly results put FCF Margin at 18.57% for Q4 2025, down 3395.0% from a year ago — trailing twelve months through Dec 2025 was 9.84% (down 657.0% YoY), and the annual figure for FY2025 was 9.81%, down 660.0%.
  • FCF Margin for Q4 2025 was 18.57% at Acadia Pharmaceuticals, down from 26.52% in the prior quarter.
  • Over the last five years, FCF Margin for ACAD hit a ceiling of 36.96% in Q4 2023 and a floor of 66.1% in Q1 2022.
  • Median FCF Margin over the past 5 years was 5.15% (2022), compared with a mean of 4.98%.
  • Biggest five-year swings in FCF Margin: soared 5444bps in 2023 and later tumbled -3395bps in 2025.
  • Acadia Pharmaceuticals' FCF Margin stood at 17.68% in 2021, then increased by 1bps to 17.48% in 2022, then surged by 311bps to 36.96% in 2023, then tumbled by -58bps to 15.38% in 2024, then plummeted by -221bps to 18.57% in 2025.
  • The last three reported values for FCF Margin were 18.57% (Q4 2025), 26.52% (Q3 2025), and 24.17% (Q2 2025) per Business Quant data.